Edition:
United States

Galectin Therapeutics Inc (GALT.OQ)

GALT.OQ on NASDAQ Stock Exchange Capital Market

6.62USD
24 Sep 2018
Change (% chg)

$0.09 (+1.38%)
Prev Close
$6.53
Open
$6.47
Day's High
$6.81
Day's Low
$6.44
Volume
125,933
Avg. Vol
170,930
52-wk High
$9.49
52-wk Low
$1.29

Chart for

About

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally... (more)

Overall

Beta: 2.55
Market Cap(Mil.): $267.17
Shares Outstanding(Mil.): 40.91
Dividend: --
Yield (%): --

Financials

  GALT.OQ Industry Sector
P/E (TTM): -- 108.33 32.69
EPS (TTM): -0.43 -- --
ROI: -190.97 1.50 12.72
ROE: -- 0.19 14.85

BRIEF-Galectin Therapeutics Proceeds To Phase 3 Development Of GR-MD-02 For NASH Cirrhosis

* GALECTIN THERAPEUTICS PROCEEDS TO PHASE 3 DEVELOPMENT OF GR-MD-02 FOR NASH CIRRHOSIS FOLLOWING FDA MEETING

May 14 2018

BRIEF-Galectin Therapeutics Q1 Loss Per Share $0.12

* GALECTIN THERAPEUTICS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 11 2018

BRIEF-Galectin Therapeutics Provides Business Update

* GALECTIN THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Mar 29 2018

Competitors

Earnings vs. Estimates